The raised guidance and strong HVP Components growth (20.3% organic) signal sustained demand for high-value injectable solutions. Monitor the West Vantage segment's continued decline (-6.6% organic) and the impact of the SmartDose divestiture on future revenue comparisons.
Price Chart
Executive Summary
West Pharmaceutical Services reported Q3 2026 adjusted-diluted EPS of $2.66, beating the $2.20 consensus by 20.9%, and net sales of $874.5M, above the $826.5M consensus. The company raised full-year 2026 net sales guidance to $3.41B-$3.42B and adjusted-diluted EPS guidance to $9.38-$9.48, reflecting strong HVP Components growth and margin expansion.
Key Financial Metrics
Key Facts
- Q3 2026 net sales of $874.5M, up 8.7% YoY (organic growth 11.9%)
- Adjusted-diluted EPS of $2.66, up 35.7% YoY, beating consensus of $2.20
- GAAP diluted EPS of $3.02, up 57.3% YoY
- HVP Components net sales of $466.7M, up 19.7% YoY (organic +20.3%)
- Full-year 2026 net sales guidance raised to $3.41B-$3.42B (from $3.345B-$3.380B)
- Full-year 2026 adjusted-diluted EPS guidance raised to $9.38-$9.48 (from $8.85-$9.05)
- Company repurchased $231M of stock in Q3, $685M year-to-date
- Quarterly dividend increased 18% to $0.26 per share
- New $950M credit agreement entered on Oct 26, 2026, replacing $130M facility
Financial Impact
EPS beat consensus by 20.9% ($2.66 vs $2.20); revenue beat consensus by 5.8% ($874.5M vs $826.5M); full-year guidance raised by $0.53-$0.43 for EPS and $65M-$40M for revenue
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Proprietary Products | $728.8M | +12.6% |
| West Vantage | $145.7M | -7.3% |
Risk Factors
- West Vantage segment net sales declined 7.3% YoY (organic -6.6%), indicating ongoing weakness
- Generics market group within Proprietary Products declined 5.7% YoY (organic -4.5%)
- Share repurchase program reduced outstanding shares by 3.1% year-to-date, potentially masking underlying operational trends
- New $950M credit facility increases debt capacity and financial flexibility but also leverage potential
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302922802 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | No price | awaiting T+60 | awaiting T+60 | No price |
Oct 29, 2026 3d ago | Press Release | $416.67 | awaiting T+60 | awaiting T+60 | $412.62 (−0.97%) |
Oct 26, 2026 6d ago | 8-K | $398.29 | awaiting T+60 | awaiting T+60 | $412.62 (+3.60%) |
Oct 26, 2026 6d ago | Institutional Cluster | $394.73 | awaiting T+60 | awaiting T+60 | $412.62 (+4.53%) |
Jul 23, 2026 14w ago | 8-K | No price | awaiting T+60 | awaiting T+60 | No price |
Jul 23, 2026 14w ago | Press Release | $355.48 $383.02 | ▲ +7.75% | ▲ +3.19% | $412.62 (+16.07%) |
Jul 7, 2026 16w ago | Press Release | $356.08 $370.76 | ▲ +4.12% | ▲ +2.13% | $412.62 (+15.88%) |
May 11, 2026 24w ago | 8-K | $311.82 $348.06 | ▼ −11.62% | ▼ −7.51% | $412.62 (−32.32%) |
Apr 27, 2026 27w ago | Insider Cluster | $300.93 $358.41 | ▲ +19.10% | ▲ +14.59% | $412.62 (+37.11%) |
Apr 27, 2026 27w ago | Insider Cluster | $300.93 $358.41 | ▲ +19.10% | ▲ +14.59% | $412.62 (+37.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers